Breaking Finance News

A statement released earlier today by Zacks Investment Research about Heat Biologics Inc (NASDAQ:HTBX) bumps the target price to $1.75

Boasting a price of $1.55, Heat Biologics Inc (NASDAQ:HTBX) traded 0.00% even on the day. With the last stock close up 60.51% relative to the 200-day average, compared with the S&P 500 which has fallen -0.01% over the same time period. The company has been tracking to a 50-day average of $1.37 and two hundred day average of $0.87. Trade volume was was down over the average, with 408,022 shares of HTBX changing hands under the typical 1,861,930 shares.

Reporting a possible upside of 0.13%, Zacks Investment Research raised the target price of Heat Biologics Inc (NASDAQ:HTBX) to $2

Previously on Wednesday June 17 2015, HC Wainright reported about Heat Biologics Inc(NASDAQ:HTBX) bumped the target price from $0.00 to $13.00. At the time, this suggested an upside of 0.84%.

See Graphic Below:

Heat Biologics Inc (NASDAQ:HTBX)

Heat Biologics Inc has a one-year low of $0.40 and a 52 week high of $5.89 and has a market cap of $0.0.

General Company Details For Heat Biologics Inc (NASDAQ:HTBX)

Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, and in combination with nivolumab (Opdivo) to treat patients with NSCLC.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *